Company Overview - Twist Bioscience's stock has experienced a significant rebound in recent months, attributed to increasing optimism surrounding AI-enabled drug discovery and the adoption of minimal residual disease (MRD) testing [1] - The Biopharma segment of Twist is reaccelerating, driven by customers engaged in AI-enabled drug discovery and next-generation sequencing (NGS) [1] Investment Strategy - Narweena, an asset management firm led by Richard Durant, focuses on identifying market dislocations caused by a poor understanding of long-term business prospects, aiming for excess risk-adjusted returns [1] - The research process at Narweena emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon [1] - The firm targets smaller cap stocks and markets where competitive advantages are not immediately apparent, driven by the belief that an aging population and low growth will create new investment opportunities [1] Market Dynamics - Many industries are expected to face stagnation or secular decline, which may paradoxically enhance business performance due to reduced competition [1] - Conversely, some businesses may encounter rising costs and diseconomies of scale, impacting their performance negatively [1] - The economy is increasingly characterized by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1]

Core Viewpoint - The first patient has been treated in the REVISE dose-ranging study by GenSight Biologics in collaboration with the 15-20 National Hospital in Paris, focusing on innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1]. Company Summary - GenSight Biologics is a biopharma company that specializes in developing and commercializing gene therapies aimed at treating retinal neurodegenerative diseases and central nervous system disorders [1]. - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1]. Industry Summary - The REVISE study is an open-label, single center trial that aims to enroll patients to evaluate the efficacy of the gene therapy being developed [1].

Summary of Innovent Biologics Conference Call Company Overview - **Company**: Innovent Biologics (1801.HK) - **Industry**: Biopharmaceuticals, focusing on oncology and immunology Key Points from the Conference Call Strategic Collaboration with Eli Lilly - Innovent announced a strategic collaboration with Eli Lilly on February 8, 2026, to advance early-stage oncology and immunology programs - The deal includes: - **Upfront Payment**: US$350 million - **Milestone Payments**: Up to US$8.5 billion - **Sales Royalties**: Tiered royalties from net sales outside of China - This collaboration marks the seventh agreement between Innovent and Eli Lilly, which began in 2015 with a three-mAb oncology deal [1][6] Roles and Responsibilities - Innovent will retain rights in China and lead the programs from concept to clinical proof of concept (POC) - Eli Lilly will manage late-stage global development and hold rights outside of China [1][2] Industry Trends - There is a growing trend of out-licensing deals from Chinese biopharma companies, indicating recognition from global partners of the potential in differentiated pipelines and fast POC delivery [1] Financial Outlook - Innovent is considered undervalued at current levels, with a market-implied weighted average cost of capital (WACC) of 12% reflecting only de-risked indications [1] - The company has a deep pipeline of over 30 assets, including commercialized products like sintilimab, a leading PD-1 inhibitor [1][6] Risks - Key risks identified include: - Intensifying competition in the PD-1/L1 market in China - Uncertain approval timelines for key candidates - Potential restrictions on off-label use due to safety issues - Failure of R&D projects [1][7] Financial Projections - **Market Capitalization**: HK$128.9 billion / US$16.5 billion - **Revenue Projections**: - 2024: Rmb 9,421.9 million - 2025: Rmb 12,783.0 million - 2026: Rmb 17,291.0 million - 2027: Rmb 20,681.3 million - **EBITDA Projections**: - 2024: (462.5) million - 2025: 1,274.8 million - 2026: 3,531.6 million - 2027: 5,106.1 million - **Price Target**: HK$102.85, representing a 29.4% upside from the current price of HK$79.50 [8] Conclusion - Innovent Biologics is positioned to maintain its leading role in the Chinese biotech sector, supported by a robust pipeline and strategic collaborations, particularly with Eli Lilly. The company faces significant risks but also presents a compelling investment opportunity given its growth potential and current valuation [1][8]

Core Insights - EpimAb Biotherapeutics has achieved its first Clinical Trial Application (CTA) filing through its partnership with Almirall, marking a significant milestone for the company [1] - Almirall has licensed EpimAb's FIT-Ig platform to develop bispecific antibodies, with the first candidate targeting IL-13 and OX-40L for atopic dermatitis expected to enter Phase 1 clinical trials in the first half of 2026 [2] - The FIT-Ig technology allows for the generation of bispecific antibodies using basic structural components of monoclonal antibodies, demonstrating the platform's versatility and potential for rapid drug development [3] Company Overview - EpimAb Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific antibodies, leveraging its proprietary FIT-Ig and MAT-Fab platforms to advance a unique pipeline targeting cancer and autoimmune diseases [4]

Core Viewpoint - Maravai LifeSciences, Inc. is set to announce its fourth quarter and full year 2025 financial and operating results on February 25, 2026, after market close, followed by a conference call and webcast [1]. Group 1: Company Overview - Maravai LifeSciences is a global provider of life science reagents and services aimed at researchers and biotech innovators [1]. - The company specializes in critical products that facilitate the development of drug therapies, diagnostics, and novel vaccines, as well as supporting research on human diseases [3]. - Maravai's subsidiaries are recognized leaders in nucleic acid synthesis and biologics safety testing, serving many of the world's top biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [3]. Group 2: Conference Call Details - The conference call can be accessed by telephone at 1-800-343-4136 or 1-203-518-9843, with the reference ID being MARAVAI [2]. - The call will also be available via live or archived webcast on the "Investors" section of Maravai's website [2].

Core Insights - DBV Technologies, a late-stage biopharmaceutical company, will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit on February 11-12, 2026, with CEO Daniel Tassé scheduled to present on February 12 at 2:30 PM ET [1] Company Overview - DBV Technologies is focused on developing treatment options for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN® patch technology [3] - The company aims to address food allergies through epicutaneous immunotherapy (EPIT), which introduces microgram amounts of biologically active compounds to the immune system via intact skin [3] - DBV's food allergy programs include ongoing clinical trials of VIASKIN® Peanut for peanut allergic toddlers (1-3 years) and children (4-7 years) [3] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] - The company's ordinary shares are traded on segment B of Euronext Paris and its American Depositary Shares (ADSs) are traded on the Nasdaq Capital Market [4]

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]

Core Viewpoint - A class action has been filed against Ultragenyx Pharmaceutical Inc. for allegedly misleading investors regarding the Phase III Orbit and Cosmic Studies for setrusumab, which tested its efficacy in treating Osteogenesis Imperfecta [1][2]. Group 1: Allegations and Misleading Information - The complaint alleges that Ultragenyx provided overly positive statements about setrusumab's expected results, claiming it would decrease the annualized fracture rate in patients with Osteogenesis Imperfecta [2]. - Defendants are accused of concealing material adverse facts about setrusumab's potential and the risks associated with the study protocols, specifically that while setrusumab increases bone density, it does not correlate with a decrease in fracture rates [3]. Group 2: Study Results and Stock Impact - On December 29, 2025, Ultragenyx announced that the Phase III Orbit and Cosmic Studies did not achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonates [4]. - Following this announcement, Ultragenyx's stock price plummeted from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025, marking a decline of approximately 42.32% in one day [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Ultragenyx and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [5].

ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a pu ...

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $172.5 million, before deducting u ...